Tirzepatide SURMOUNT-1 (2022) and SURPASS-2 (2021) SURMOUNT-1 (Jastreboff et al., NEJM 2022): 2,539 non-diabetic adults with BMI 30, 72 weeks of tirzepatide 15 mg/week: Weight loss: 20.9% (vs 3.1% placebo) 91% of participants 5% loss, 56.7% 20% SURPASS-2 (Fras et al., NEJM 2021): 1,879 T2D patients head-to-head vs semaglutide 1 mg: HbA1c: 2.30% (tirzepatide 15 mg) vs 1.86% (semaglutide) Weight loss: 11.2 kg vs 5.7 kg Tirzepatide statistically outperforms semaglutide on both HbA1c and weight in a head-to-head trial a rare outcome in incretin pharmacology
Bacteria such as Lactobacillaceae and Bifidobacteriaceae species have been reported to produce riboflavin that can be used by colonic epithelial cells, but the magnitude of their in situ contribution in the gut is not yet clear 30,31
These drugs have outsold, or are projected to outsell, other lifestyle-based drugs, such as Viagra and Prozac, the report says
Winning the Hearts of Patients and Providers Novo Nordisks success hinges on its ability to resonate with three key stakeholders: patients, healthcare providers, and payers